Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma. This evidence concerns the gene MAP2K2 and pancreatic ductal adenocarcinoma.